| Literature DB >> 25540720 |
Trang Dinh Van1, Quynh-Dao Dinh2, Phu Dinh Vu1, Trung Vu Nguyen1, Ca Van Pham1, Trinh Tuyet Dao1, Cam Dac Phung3, Ha Thu Thi Hoang3, Nga Thi Tang3, Nga Thuy Do2, Kinh Van Nguyen1, Heiman Wertheim4.
Abstract
Acinetobacter calcoaceticus-baumannii complex is a common cause of hospital-acquired infections (HAIs) globally, remarkable for its high rate of antibiotic resistance, including to carbapenems. There are few data on the resistance of A. baumannii in Vietnam, which are essential for developing evidence-based treatment guidelines for HAIs. Antibiotic susceptibility testing was conducted by VITEK®2, and pulsed-field gel electrophoresis (PFGE) was performed on 66 clinical A. baumannii complex isolates recovered during 2009 at the National Hospital of Tropical Diseases (NHTD), a referral hospital in Hanoi, Vietnam. Basic demographic and clinical data were collected and analysed using descriptive statistics. Most isolates came from lower respiratory tract specimens (59; 89.4%) from intensive care unit (ICU) patients [64/65 (98.5%) with available data] who had been admitted to NHTD for ≥2 days [42/46 (91.3%) with available data]. More than 90% of the isolates were resistant to the tested β-lactamase/β-lactamase inhibitors, cephalosporins, carbapenems, fluoroquinolones and trimethoprim/sulfamethoxazole. Moreover, 25.4% (16/63) were resistant to all tested β-lactams, quinolones and aminoglycosides. All isolates remained sensitive to colistin and 58.7% were susceptible to tigecycline. Of the 66 isolates, 49 could be classified into eight PFGE types (A-H). Every PFGE type, except D, had cluster(s) of three or more isolates with a temporal relationship. In conclusion, these data suggest a significant rise in A. baumannii antibiotic resistance in Vietnam. Clustering within PFGE types supports cross-transmission of A. baumannii within the ICU at NHTD. Increased research and resources in optimising treatment, infection control and antibiotic stewardship are needed.Entities:
Keywords: Acinetobacter baumannii; Antibiotic resistance; Genotype; Hospital-acquired infection; Ventilator-associated pneumonia
Year: 2014 PMID: 25540720 PMCID: PMC4270437 DOI: 10.1016/j.jgar.2014.05.003
Source DB: PubMed Journal: J Glob Antimicrob Resist ISSN: 2213-7165 Impact factor: 4.035
Antibiotic susceptibility testing of 63 Acinetobacter baumannii isolates at the National Hospital of Tropical Diseases (Hanoi, Vietnam), 2009.
| Antibiotic | Susceptible | Intermediate | Resistant | |||
|---|---|---|---|---|---|---|
| % | % | % | ||||
| AMC | 0.0 | 0 | 0.0 | 0 | 100.0 | 63 |
| TZP | 1.6 | 1 | 3.2 | 2 | 95.2 | 60 |
| Cefotaxime | 0.0 | 0 | 1.6 | 1 | 98.4 | 62 |
| Ceftazidime | 0.0 | 0 | 1.6 | 1 | 98.4 | 62 |
| Cefepime | 0.0 | 0 | 1.6 | 1 | 98.4 | 62 |
| Imipenem | 7.9 | 5 | 0.0 | 0 | 92.1 | 58 |
| Meropenem | 7.9 | 5 | 0.0 | 0 | 92.1 | 58 |
| Gentamicin | 17.5 | 11 | 27.0 | 17 | 55.6 | 35 |
| Tobramycin | 31.7 | 20 | 25.4 | 16 | 42.9 | 27 |
| Ciprofloxacin | 1.6 | 1 | 0.0 | 0 | 98.4 | 62 |
| Levofloxacin | 1.6 | 1 | 7.9 | 5 | 90.5 | 57 |
| Tigecycline | 58.7 | 37 | 38.1 | 24 | 3.2 | 2 |
| Colistin | 100.0 | 63 | 0.0 | 0 | 0.0 | 0 |
| SXT | 0.0 | 0 | 0.0 | 0 | 100.0 | 63 |
AMC, amoxicillin/clavulanic acid; TZP, piperacillin/tazobactam; SXT, trimethoprim/sulfamethoxazole.
Fig. 1Clustering of Acinetobacter calcoaceticus–baumannii complex isolates in 2009 at the National Hospital of Tropical Diseases (Hanoi, Vietnam) within pulsed-field gel electrophoresis (PFGE) types A–C and E–H. * Indicates cluster isolates.
Antibiotic susceptibility patternsa according to pulsed-field gel electrophoresis (PFGE) type.
| Antibiotic/antibiotic class | PFGE type | |||||||
|---|---|---|---|---|---|---|---|---|
| A (6) | B | C (15) | D (3) | E (4) | F (4) | G | H (5) | |
| β-Lactamase/β-lactamase inhibitors | R | R | R | R | R | R | R | R |
| Cephalosporins | R | R | R | R | R | R | R | R |
| Carbapenems | R | r/s | R | R | R | R | R | R |
| Gentamicin | R | r/i/s | r/i | R | R | R | r/i/s | r/i |
| Tobramycin | R | r/s | r/i/s | i/s | R | r/i | r/s | i/s |
| Fluoroquinolones | R | R | R | R | r/i | R | R | R |
| Tigecycline | S | S | I | i/s | i/s | S | S | r/i/s |
| Colistin | S | S | S | S | S | S | S | S |
| SXT | R | R | R | R | R | R | R | R |
R, resistant; I, intermediate; S, susceptible; SXT, trimethoprim/sulfamethoxazole.
Susceptibility phenotypes reported in non-capitalised letters and separated by a slash indicate varying susceptibility patterns within that cluster of strains.
Antibiotic testing data were missing for one isolate.